Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Brief: EMA's CHMP Recommends Authorising Ronapreve And Regkirona For COVID-19

Nov 11 (Reuters) - European Medicines Agency:
    * EMA: COVID-19: EMA RECOMMENDS AUTHORISATION OF TWO
MONOCLONAL
ANTIBODY MEDICINES: 11/11/2021
    * EMA’S HUMAN MEDICINES COMMITTEE (CHMP) HAS RECOMMENDED
AUTHORISING RONAPREVE (CASIRIVIMAB/IMDEVIMAB) AND REGKIRONA
(REGDANVIMAB) FOR COVID-19.
    * EMA - CHMP RECOMMENDED AUTHORISING RONAPREVE FOR TREATING
COVID-19 IN ADULTS, ADOLESCENTS WHO DO NOT REQUIRE SUPPLEMENTAL
OXYGEN AND WHO ARE AT INCREASED RISK
    * EMA - SAFETY PROFILE OF BOTH MEDICINES FAVOURABLE WITH A
SMALL
NUMBER OF INFUSION-RELATED REACTIONS
    * EMA - CHMP CONCLUDED THAT BOTH MEDICINES’ BENEFITS ARE
GREATER
THAN THEIR RISKS FOR THEIR APPROVED USES
    * EMA SAYS CHMP WILL NOW SEND ITS RECOMMENDATIONS FOR BOTH
MEDICINES TO EUROPEAN COMMISSION FOR RAPID LEGALLY BINDING
DECISIONS.
    * EMA: RONAPREVE CAN ALSO BE USED FOR PREVENTING COVID-19 IN
PEOPLE AGED 12 YEARS AND OLDER WEIGHING AT LEAST 40 KILOGRAMS.
    * EMA SAYS WITH REGARD TO REGKIRONA, COMMITTEE RECOMMENDED
AUTHORISING MEDICINE FOR TREATING ADULTS WITH COVID-19 WHO DO
NOT REQUIRE SUPPLEMENTAL OXYGEN


 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Celltrion Healthcare Co

See all news